Objective 
Introduction
A substantial part of the workload of any general practitioner is the management of depression. 2 Antidepressant drug treatment is the most common treatment for depressive illness used by general practitioners, ' '2 Social and relationship problems are prevalent among depressed patients seeing their general practitioner,8"'-"' and psychological treatments may be more appropriate than drug treatment. Intervention by a social worker attached to a general practice was shown to be as effective as routine management by general practitioner in young depressed women.'2 Cognitive behaviour therapy, which relies on problem solving strategies, has been shown to be more effective than antidepressant drug therapy alone'6 and "treatment as usual"'7 in primary care. The investment of time and skill required by both social work intervention and cognitive behaviour therapy is quite unlike the routine management of depressed patients in primary care: most patients see their doctor for less than 10 minutes on the first occasion. ' Hamilton score less than 7.25 An "intention to treat" analysis was used in the comparison ofrecovery ratesthat is, patients who refused to continue treatment were classified as "not recovered." Differences in depression ratings and recovery rates were assessed using 95% and 99% confidence intervals.
Results

RANDOMISATION
The treatment groups were similar in most demographic and clinical details (tables I and II). Only two (7%) of the patients randomised to cognitive behaviour therapy had a history of treatment for depressive illness, which was a much smaller proportion than in the other treatments, and the proportion ofmen among the patients allocated to amitriptyline was twice as great as among those allocated to cognitive therapy or social work counselling.
PATIENTS REFUSING TREATMENT
Five of the seven patients who refused to start specialist treatment after randomisation were in the group allocated to amitriptyline prescribed by the psychiatrist. One patient randomised to routine general practitioner care did not make an appointment to see BMJ VOLUME 304 
CLINICAL EFFICACY
The average severity of depression measured by Hamilton score was least in the group treated by social work counselling (table III) and, unlike the other treatment groups, only a minority of patients (n= 11) had an initial Hamilton score greater than 16-a common inclusion criterion for outpatient studies of depression.'5 After four weeks, amitriptyline prescribed by a psychiatrist produced significantly better results than routine general practitioner care in both Hamilton score (table III) and recovery rate (table IV) , whereas social work counselling produced a significantly better recovery rate. After 16 weeks only social work counselling was superior to general practitioner care, but twice as many patients who received routine general practitioner care had an initial Hamilton score greater than 16 (n=22). Of the more depressed patients, nine out of 11 treated by social work counselling recovered by 16 weeks compared with only nine out of 22 treated by routine general practitioner care (not statistically significant). Both of these patients who did not recover with social work counselling were men. Unfortunately, the number of men in the study was too small to make any firm conclusion about the effect of sex on clinical efficacy.
Of the patients allocated to routine general practitioner care, there was no difference in clinical outcome between those patients who took a therapeutic dose of an antidepressant drug and those who did not.
Clinical efficacy was assessed separately in the 22 patients (18% of all patients) who met the DSM-III criteria for melancholia (table V) (table VI) . Although both cognitive behaviour therapy and social work counselling involved more face to face contact than amitriptyline treatment from the psychiatrist, the total costs of the three specialist treatments were similar because clinical psychologists and social workers are less expensive to employ by the hour. Face to face contact with the specialist therapists cost about four times as much as the cost of the time the general practitioners themselves spent with the patients. General practitioner care, however, made use of other NHS personnel and resources: three patients were BMJ VOLUME 304 4 APRIL 1992referred to and seen at a psychiatric outpatient clinic (staff costs £142), one patient was referred to a psychiatric outpatient clinic and attended a psychiatric day hospital (estimated cost £444), and one patient was referred to a primary care health visitor (£33 tWhen cost of amitriptyline was included mean cost was £120.
tWhen drug costs were included mean cost was £34. When use of other NHS staff and resources was also included mean cost was £55. A major aim of the present study was to measure the routine length of the patient-therapist contact involved in each treatment, and so no attempt was made to standardise therapeutic attention among the treatments. Consequently, it cannot be assumed that any slight advantage for one of the specialist treatments depended on the defining characteristics of the treatment rather than the length of therapeutic attention. 7 Most patients rated the results of their treatment positively, but few said they would want the same treatment again. Perhaps this reflects a dislike of being depressed or fears about the possibility of future episodes. Such fears are realistic because most outpatients who recover from an episode of depression will suffer a recurrence of illness within two years despite continuation treatment with antidepressant drugs.27 Depressed patients treated by cognitive behaviour therapy may be less likely to relapse than patients treated with antidepressant drugs alone over one28 and two29 years after the index episode. The potential longer term benefits of social work counselling have not been assessed. If social work counselling or cognitive therapy helps patients to cope more effectively with the problems that led to their depression this may prevent further episodes of depression. Until we have measured relapse rates after treatment our cost-benefit analysis is incomplete.
